Compare CSTM & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTM | CRNX |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | France | United States |
| Employees | 11500 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.9B |
| IPO Year | 2012 | 2018 |
| Metric | CSTM | CRNX |
|---|---|---|
| Price | $32.75 | $36.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $30.75 | ★ $76.75 |
| AVG Volume (30 Days) | ★ 1.9M | 934.6K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 405.26 | N/A |
| EPS | ★ 1.42 | N/A |
| Revenue | ★ $8,449,000,000.00 | $1,039,000.00 |
| Revenue This Year | $21.46 | $720.10 |
| Revenue Next Year | $0.50 | $184.67 |
| P/E Ratio | $23.43 | ★ N/A |
| Revenue Growth | ★ 15.19 | N/A |
| 52 Week Low | $13.04 | $25.83 |
| 52 Week High | $36.99 | $57.99 |
| Indicator | CSTM | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 53.97 |
| Support Level | $32.24 | $33.14 |
| Resistance Level | $36.86 | $44.89 |
| Average True Range (ATR) | 1.57 | 1.59 |
| MACD | -0.30 | 0.37 |
| Stochastic Oscillator | 12.72 | 75.37 |
Constellium SE is engaged in the development, manufacture and sale of a broad range of high value-added specialty rolled and extruded aluminum products to the aerospace, space, defense, packaging, automotive, commercial transportation and general industrial end-markets. Its business model is to add value by converting aluminum into semi-fabricated and, in some instances, fully-fabricated alloyed aluminum products that meet stringent and performance-critical requirements from customers. It operates through three segments: Aerospace & Transportation Operating Segment, Packaging & Automotive Rolled Products Operating Segment, and Automotive Structures & Industry Operating Segment. It serves Aerospace, Packaging and Automotive and operates in the United States, France, Germany and others.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.